Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
Rieke E AltenEugen FeistHanns-Martin LorenzHubert NüßleinReinhard E VollMelanie ChartierYedid ElbezChristiane RauchPublished in: Clinical rheumatology (2019)
• Analyses of data from national patient cohorts provide insight on local treatment patterns. • In the German cohort of the ACTION study, abatacept retention at 2 years was similar in biologic-naïve and biologic-failure patients. • Biologic-naïve patients from the German cohort had a significantly lower abatacept retention rate and a trend of lower good/moderate EULAR response rate than patients from other countries. • Data from large international studies may not be directly applicable to individual countries.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- electronic health record
- disease activity
- patient reported outcomes
- machine learning
- systemic sclerosis
- artificial intelligence
- high intensity
- interstitial lung disease
- rheumatoid arthritis patients
- data analysis
- replacement therapy